At a glance

Most Recent Events

31 May 2017
Results (n= 452) assessing optimal lenvatinib dose based on population PK and exposure-response analysis using using pooled data from NCT00946153, NCT00121719, NCT00121680, NCT00280397, NCT01268293 and other 8 phase 1 studies in healthy adults, published in the Journal of Clinical Pharmacology

21 Jan 2017
Results of subgroup analysis of the phase 2 part of this study (NCT00946153) presented at the 2017 Gastrointestinal Cancers Symposium